ASCO Article28 May 2025 10:01
Cizzle Bio’s recent presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting has spotlighted their groundbreaking CIZ1B blood test, marking a pivotal moment in early lung cancer detection. 
🚀 Transformative Potential for Lung Cancer Screening
The ASCO study abstract reveals that integrating the CIZ1B test into lung cancer screening protocols could save the U.S. Medicare program up to $518 million annually. This is achieved by enhancing early-stage detection and reducing unnecessary procedures. The test boasts a 95% sensitivity for Stage I lung cancer and a 96% negative predictive value, making it a powerful tool for early diagnosis.   
💡 A Game-Changer for High-Risk Populations
Traditional low-dose CT (LDCT) scans, while effective, have a high false-positive rate and low uptake among eligible patients. The simplicity and accuracy of the CIZ1B blood test address these challenges, potentially increasing screening participation by 15% among high-risk Medicare populations.  
📈 Strategic Growth and Market Expansion
Beyond clinical benefits, Cizzle Bio’s strategic licensing agreements and partnerships are positioning the company for significant growth. Their exclusive licensing agreement with Cizzle Bio Inc. for North America includes guaranteed minimum advance royalty payments and plans for a U.S. launch in 2025. 
In summary, the ASCO presentation underscores Cizzle Bio’s CIZ1B test as a transformative advancement in lung cancer diagnostics, with the potential to improve patient outcomes and reduce healthcare costs significantly.